SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:b9de9bcd-e639-45a9-a5b1-19798046c884"
 

Search: onr:"swepub:oai:lup.lub.lu.se:b9de9bcd-e639-45a9-a5b1-19798046c884" > Impact of Neoadjuva...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Impact of Neoadjuvant Therapy for Pancreatic Cancer : Transatlantic Trend and Postoperative Outcomes Analysis

Davis, Catherine H. (author)
Baylor Scott and White Hospital,Baylor Scott & White Hlth, TX USA
Augustinus, Simone (author)
University of Amsterdam,Univ Amsterdam, Netherlands
de Graaf, Nine (author)
University of Amsterdam,Univ Amsterdam, Netherlands
show more...
Wellner, Ulrich F. (author)
University Medical Center Schleswig-Holstein,Pancreas & Clin Surg, Germany
Johansen, Karin (author)
Linköpings universitet,Linköping University,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten
Andersson, Bodil (author)
Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lever-, pankreas- och gallvägskirurgi,Forskargrupper vid Lunds universitet,Artificiell intelligens och thoraxkirurgisk vetenskap (AICTS),LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Hepato-Pancreato-Biliary Surgery,Lund University Research Groups,Artificial Intelligence in CardioThoracic Sciences (AICTS),LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital,Lund Univ, Sweden; Lund Univ, Sweden; Skane Univ Hosp, Sweden
Beane, Joal D. (author)
Ohio State University,Ohio State Univ, OH USA
Björnsson, Bergthor (author)
Linköpings universitet,Linköping University,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Kirurgiska kliniken US
Busch, Olivier R. (author)
Baylor Scott and White Hospital,Univ Amsterdam, Netherlands
Gleeson, Elizabeth M. (author)
University of North Carolina,Univ N Carolina, NC USA
van Santvoort, Hjalmar C. (author)
University Medical Center Utrecht,Univ Med Ctr Utrecht, Netherlands
Tingstedt, Bobby (author)
Linköpings universitet,Linköping University,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten
Williamsson, Caroline (author)
Linköpings universitet,Linköping University,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten
Keck, Tobias (author)
University Medical Center Schleswig-Holstein,Pancreas & Clin Surg, Germany
Besselink, Marc G. (author)
Baylor Scott and White Hospital,Univ Amsterdam, Netherlands
Koerkamp, Bas Groot (author)
Erasmus University Medical Center,Erasmus MC, Netherlands
Pitt, Henry A. (author)
Rutgers Robert Wood Johnson Med Sch, NJ USA; 125 Little Albany St, NJ 08901 USA
show less...
 (creator_code:org_t)
 
LIPPINCOTT WILLIAMS & WILKINS, 2024
2024
English 9 s.
In: Journal of the American College of Surgeons. - : LIPPINCOTT WILLIAMS & WILKINS. - 1879-1190 .- 1072-7515. ; 238:4, s. 613-621
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BACKGROUND: The introduction of modern chemotherapy a decade ago has led to increased use of neoadjuvant therapy (NAT) in patients with pancreatic ductal adenocarcinoma (PDAC). A recent North American study demonstrated increased use of NAT and improved operative outcomes in patients with PDAC. The aims of this study were to compare the use of NAT and short-term outcomes in patients with PDAC undergoing pancreatoduodenectomy (PD) among registries from the US and Canada, Germany, the Netherlands, and Sweden. STUDY DESIGN: Databases from 2 multicenter (voluntary) and 2 nationwide (mandatory) registries were queried from 2018 to 2020. Patients undergoing PD for PDAC were compared based on the use of upfront surgery vs NAT. Adoption of NAT was measured in each country over time. Thirty-day outcomes, including the composite measure (ideal outcomes), were compared by multivariable analyses. Sensitivity analyses of patients undergoing vascular resection were performed. RESULTS: Overall, 11,402 patients underwent PD for PDAC with 33.7% of patients receiving NAT. The use of NAT increased steadily from 28.3% in 2018 to 38.5% in 2020 (p < 0.0001). However, use of NAT varied widely by country: the US (46.8%), the Netherlands (44.9%), Sweden (11.0%), and Germany (7.8%). On multivariable analysis, NAT was significantly (p < 0.01) associated with reduced rates of serious morbidity, clinically relevant pancreatic fistulae, reoperations, and increased ideal outcomes. These associations remained on sensitivity analysis of patients undergoing vascular resection. CONCLUSIONS: NAT before PD for pancreatic cancer varied widely among 4 Western audits yet increased by 26% during 3 years. NAT was associated with improved short-term outcomes.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view